Items Tagged ‘Stage IV Pancreatic Cancer’

August 17th, 2016

Pancreatic Cancer Cells Find Unique Fuel Sources to Keep from Starving

By

Pancreatic cancer cells avert starvation in dense tumors by ordering nearby support cells to supply them with an alternative source of nutrition. This is the finding of a study in cancer cells and mice published August 10 in Nature. The study was led by researchers from NYU Langone Medical Center, the Dana Farber Cancer Institute […]

View full entry

Tags: autophagy, fuel, HCQ, News, Pancreatic Cancer, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer, Stages I-III Pancreatic Cancer, stellate cells, study, tumors


November 3rd, 2015

Onivyde Approved for Pancreatic Cancer

By

The United States Food and Drug Administration (FDA) approved Onivyde (irinotecan liposome injection) to be used in combination with fluorouracil and leucovorin for patients with advanced pancreatic cancer. The approval is indicated for patients with pancreatic cancer that has spread to distant sites in the body who have received prior treatment with the chemotherapy agent, […]

View full entry

Tags: advanced, fluorouracil, irinotecan liposome injection, leucovorin, News, Onivyde, Pancreatic Cancer, Stage IV Pancreatic Cancer


November 26th, 2014

MM-398 Receives Fast Track Designation for Advanced Pancreatic Cancer

By

The U. S. Food and Drug Administration (FDA) has granted MM- 398 plus 5-fluorouracil (5-FU) and leucovorin a Fast Track designation as a second-line treatment for patients with metastatic pancreatic cancer, based on data from the phase III NAPOLI-1 study that were presented at the 2014 World Congress on Gastrointestinal Cancer in June 2014. MM-398 […]

View full entry

Tags: mm-398, News, Pancreatic Cancer, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer


October 7th, 2014

FDA Grants Orphan Drug Designation to Investigational Agent for Pancreatic Cancer

By

Pancreatic cancer is one of the deadliest forms of cancer. Each year, approximately 43,000 people are diagnosed with pancreatic cancer in the United States and close to 37,000 die from the disease. The disease is often diagnosed at an advanced stage, and treatment of advanced disease remains challenging. The current standard of care consists of […]

View full entry

Tags: News, Pancreatic Cancer, pegph2, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer


September 23rd, 2014

Simtuzumab Fails to Improve Outcomes in Pancreatic Cancer

By

Pancreatic cancer is one of the deadliest forms of cancer. Each year, approximately 43,000 people are diagnosed with pancreatic cancer in the United States and close to 37,000 die from the disease. The disease is often diagnosed at an advanced stage, and treatment of advanced disease remains challenging. Gemzar has been a standard chemotherapy drug […]

View full entry

Tags: gemzar, gilead, News, Pancreatic Cancer, Recurrent Pancreatic Cancer, simtuzuma, Stage IV Pancreatic Cancer


July 10th, 2014

In Advanced Pancreatic Cancer, Eloxatin® with Folinic Acid and Fluorouracil May Improve Survival

By

In a Phase III study, the addition of the chemotherapy drug Eloxatin® (oxaliplatin) to the chemotherapy regimen of folinic acid and fluorouracil (5-FU) improved outcomes in patients with advanced pancreatic cancer that had progressed on Gemzar® (gemcitabine). These findings were recently published in Journal of Clinical Oncology. Pancreatic cancer is one of the deadliest forms […]

View full entry

Tags: eloxatin, gemzar, News, Pancreatic Cancer, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer


July 1st, 2014

Updated Analysis of the MPACT Study in Advanced Pancreatic Cancer Demonstrates Continued Improvement in Survival for Abraxane-based Chemotherapy

By

A follow up report on the results of the Metastatic Pancreatic Adenocarcinoma Clinical Trial (MPACT) study of Abraxane® (nab-paclitaxel) in combination with Gemzar® (gemcitabine) in previously untreated patients with metastatic pancreatic cancer was presented recently at the annual American Society of Clinical Oncology meeting in Chicago.1  Results of the study were initially reported in the New England Journal of Medicine.2 Pancreatic cancer […]

View full entry

Tags: abraxane, gemzar, News, Pancreatic Cancer, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer


June 2nd, 2014

Jakafi Plus Capecitabine Improves Survival in Metastatic Pancreatic Cancer Patients with Local and Systemic Inflammation

By

In a study presented at the 2014 ASCO meeting and published in the Journal of Clinical Oncology, researchers reported that treatment with Jakafi® (ruxolitinib) plus capecitabine improved overall survival and progression-free survival in metastatic pancreatic cancer patients with local and systemic inflammation (INFL). INFL is a common marker of cancer that is associated with adverse prognoses […]

View full entry

Tags: jakafi, News, Pancreatic Cancer, ruxolitinib, Stage IV Pancreatic Cancer, Stages I-III Pancreatic Cancer


May 23rd, 2014

Radioimmunotherapy and Gemcitabine Combination Shows Extended Survival Times for Metastatic Pancreatic Ductal Cancer Patients

By

In a recent study presented at the American Association for Cancer Research conference on Pancreatic Cancer: Innovation in Research and Treatment, researchers reported that a combination therapy of gemcitabine and radioimmunotherapy (fractionated doses of (90Y-clivatuzumab tetraxetan) given to metastatic pancreatic ductal cancer patients improved survival times over patients who received only radioimmunotherapy. The study was […]

View full entry

Tags: News, Pancreatic Cancer, Stage IV Pancreatic Cancer, Stages I-III Pancreatic Cancer


February 5th, 2014

Dual Vaccines Prolong Survival in Metastatic Pancreatic Cancer

By

The sequential delivery of two vaccines—GVAX and CRS-207—prolonged survival in patients with metastatic pancreatic cancer by about two months, according to the results of a study presented at the 2014 Gastorintestinal Cancers Symposium in San Francisco, California. Pancreatic cancer is one of the deadliest forms of cancer. Each year, approximately 43,000 people are diagnosed with […]

View full entry

Tags: News, Pancreatic Cancer, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer


December 25th, 2013

Abraxane Plus Gemzar Improves Survival in Metastatic Pancreatic Cancer

By

Abraxane® (nab-paclitaxel) plus Gemzar® (gemcitabine) improved overall and progression-free survival in patients with previously untreated metastatic pancreatic cancer, according to the results of a study published in the New England Journal of Medicine. Pancreatic cancer is one of the deadliest forms of cancer. Each year, approximately 43,000 people are diagnosed with pancreatic cancer in the […]

View full entry

Tags: News, Pancreatic Cancer, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer


September 20th, 2013

Abraxane Approved for Metastatic Pancreatic Cancer

By

The U.S. Food and Drug Administration (FDA) has approved Abraxane® (paclitaxel protein-bound particles for injectable suspension, albumin-bound) for the treatment of patients with metastatic pancreatic cancer. Pancreatic cancer is one of the deadliest forms of cancer. Each year, approximately 45,000 people are diagnosed with pancreatic cancer in the United States and close to 38,000 die […]

View full entry

Tags: News, Pancreatic Cancer, Stage IV Pancreatic Cancer


February 13th, 2013

Abraxane Improves Survival in Pancreatic Cancer

By

Abraxane® (nab-paclitaxel) prolonged life in patients with metastatic pancreatic cancer by an average of two months longer than chemotherapy and significantly increased the percentage of patients who survived for up to two years, according to the results of a study presented at the 2013 Gastrointestinal Cancers Symposium in San Francisco. Pancreatic cancer is one of […]

View full entry

Tags: News, Pancreatic Cancer, Stage IV Pancreatic Cancer


June 2nd, 2011

Sutent Approved for Pancreatic Neuroendocrine Tumors (PNET)

By

The US Food and Drug Administration has approved the targeted drug Sutent® (sunitinib) for the treatment pancreatic neuroendocrine tumors (PNET). Pancreatic neuroendocrine tumors are an uncommon type of cancer that develops in the hormone-producing cells of the pancreas. Sutent—which is taken orally—inhibits multiple biologic pathways involved in the growth, replication, and spread of cancer cells. […]

View full entry

Tags: News, Pancreatic Cancer, Stage IV Pancreatic Cancer, Stages I-III Pancreatic Cancer


May 18th, 2011

Novel Chemotherapy Regimen Outperforms Gemzar for Pancreatic Cancer

By

For people with metastatic pancreatic cancer, the chemotherapy combination known as FOLFIRINOX results in better overall survival than standard treatment with Gemzar® (gemcitabine), but also increases side effects. These results were published in the New England Journal of Medicine. Pancreatic cancer is one of the deadliest forms of cancer. Each year, approximately 43,000 people are […]

View full entry

Tags: News, Pancreatic Cancer, Stage IV Pancreatic Cancer